SEC Filing Summary: GSK Plc (Form 6-K)
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated June 18, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on June 17, 2025, pursuant to a non-discretionary agreement with Merrill Lynch International entered into on June 4, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital allocation via share buybacks and does not report operational financial metrics such as revenue, profit, or cash flow.
- Shares Purchased (June 17, 2025): 458,818 ordinary shares.
- Price Range: Lowest 1,465.00 GBp; Highest 1,485.00 GBp.
- Volume-Weighted Average Price: 1,476.46 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (Since June 4, 2025): 3,723,327 ordinary shares.
- Treasury Shares Held: 221,857,710 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,093,443,879 ordinary shares.
- Treasury Voting Rights: 5.42% of total voting rights.
Material Changes
The filing reports a reduction in the number of shares in issue and an increase in treasury shares held by the company. The percentage of voting rights attributable to treasury shares stands at 5.42% following this transaction. No material changes to revenue, debt, or liquidity are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results.
Investor Verification Checklist
- Verify the total remaining authorization under the existing buyback programme.
- Confirm the impact of the 5.42% treasury holding on earnings per share (EPS) calculations.
- Review the referenced 2024 Form 20-F and Q1 2025 Results for broader risk factors and operational performance.
- Monitor subsequent filings for the completion date of the non-discretionary agreement with Merrill Lynch International.